ArticleCureus2025
Exploratory Investigation of Predictive Factors for Reducing Adverse Effects in CapeOX Therapy for Colorectal Cancer Patients.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association Between Perioperative Inflammatory Trajectories and Postoperative Hirschsprung-Associated Enterocolitis: Insights from Group-Based Trajectory Modeling.Journal of inflammation research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOxaliplatin infusion plus oral capecitabine (CapeOX) is the standard chemotherapy regimen for colorectal cancer. It is commonly employed as adjuvant therapy and as first-line treatment for advanced disease. However, adverse effects, such as peripheral neuropathy, hand-foot syndrome, and gastrointestinal symptoms, may lead to dose reduction or discontinuation. Identifying reliable predictors of these adverse effects would support prophylactic strategies and enable safer, more personalized treatment.
methodsWe retrospectively analyzed 108 colorectal cancer patients who received CapeOX between September 2020 and October 2023. Adverse events after the first cycle were evaluated using Common Terminology Criteria for Adverse Events (CTCAE) v5.0 and categorized into Grade 0 and Grade ≥ 1 groups. Associations between pre-treatment blood test values (including aspartate aminotransferase (AST), alanine aminotransferase (ALT), red blood cells, monocytes, and basophils) and inflammatory or nutritional indices (including prognostic nutrition index (PNI), systemic inflammatory response index (SIRI), neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR)) were examined for adverse events. Variables demonstrating significant associations in univariate analysis were included in a multivariate logistic regression model. Receiver operating characteristic analysis was performed to determine optimal cut-off values of predictive markers.
resultsAST ≤ 22.0 IU/L was identified as a significant predictor of peripheral neuropathy. Nausea was significantly associated with a basophil count ≥ 0.28 × 10²/μL and occasional alcohol intake; anorexia with a basophil count ≥ 0.29 × 10²/μL and PLR ≤ 152.69; and diarrhea with a SIRI ≤ 0.37. These markers enabled effective risk stratification of adverse drug reactions in patients undergoing CapeOX.
conclusionsCertain adverse effects of CapeOX may be predicted using routine pre-treatment laboratory data. These findings could facilitate early identification of high-risk patients and enable personalized preventive interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.